858 — Extrawell Pharmaceutical Holdings Cashflow Statement
0.000.00%
- HK$209.10m
- -HK$644.56m
- HK$55.43m
- 46
- 93
- 44
- 69
Annual cashflow statement for Extrawell Pharmaceutical Holdings, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -120 | 132 | 131 | -160 | 225 |
| Depreciation | |||||
| Non-Cash Items | 110 | -145 | -141 | 153 | -233 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.03 | 2.12 | 2.95 | -6.55 | -4.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -0.852 | -1.77 | 1.18 | -3.69 | -4.37 |
| Capital Expenditures | -0.721 | -9.63 | -6.62 | -1.2 | -3.07 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.677 | 0.252 | -1.82 | 3.24 | -6.31 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.044 | -9.38 | -8.44 | 2.04 | -9.38 |
| Financing Cash Flow Items | -0.212 | -0.135 | -0.092 | -0.294 | -0.193 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1.9 | -1.94 | -2.39 | -6.5 | -1.58 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.273 | -14.8 | -9.48 | -8.79 | -15.8 |